Immunotherapy in colorectal cancer

References

• Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10–30
   PubMed Web of Science ®Google Scholar
• Huber CH, Wolfel T. Immmunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 2004; 130: 367–74
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909–15
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281–7
   PubMed Web of Science ®Google Scholar
• Chen W, Rains N, Young D, Stubbs RS. Dendritic cell-based cancer immunotherapy: potential for treatment of colorectal cancer?. J Gastroenterol Hepatol 2000; 15: 698–705
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001; 250: 462–75
   PubMed Web of Science ®Google Scholar
• Mocellin S, Rossi CR, Lise M, Nitti D. Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology 2004; 127: 1821–37
   PubMed Web of Science ®Google Scholar
• Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003; 21: 873–86
   PubMed Web of Science ®Google Scholar
• Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004; 53: 275–306
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006; 12: 3064–9
   PubMed Web of Science ®Google Scholar
• Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005; 16: 847–62
   PubMed Web of Science ®Google Scholar
• Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137: 1142–62
   PubMed Web of Science ®Google Scholar
• Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop Relat Res 1893; 1991: 3–11
   Google Scholar
• Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980; 124: 38–40
   PubMed Web of Science ®Google Scholar
• Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000; CD001986.
   PubMedGoogle Scholar
• Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg 2004; 198: 685–96
   PubMed Web of Science ®Google Scholar
• Yip D, Strickland AH, Karapetis CS, Hawkins CA, Harper PG. Immunomodulation therapy in colorectal carcinoma. Cancer Treat Rev 2000; 26: 169–90
   PubMed Web of Science ®Google Scholar
• Halak BK, Maguire HC, Jr, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999; 59: 911–7
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007; 26: 3661–78
   PubMed Web of Science ®Google Scholar
• Saif MW, Kang SP, Chu E. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. Oncology (Williston Park) 2006; 20: 11–9
   PubMedGoogle Scholar
• Aulitzky WE, Huber C, Peschel C. Cytokine therapy of neoplastic and inflammatory disease. Int Arch Allergy Immunol 1993; 101: 221–6
   PubMed Web of Science ®Google Scholar
• Eckert K, Grunberg E, Immenschuh P, Garbin F, Kreuser ED, Maurer HR. Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1. J Cancer Res Clin Oncol 1997; 123: 420–8
   PubMed Web of Science ®Google Scholar
• Holcombe RF, Li A, Stewart RM. Levamisole and interleukin-2 for advanced malignancy. Biotherapy 1998; 11: 255–8
   PubMedGoogle Scholar
• Hill HC, Conway TF, Jr, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002; 62: 7254–63
   PubMed Web of Science ®Google Scholar
• Wilson JA. Tumor necrosis factor alpha and colitis-associated colon cancer. N Engl J Med 2008; 358: 2733–4
   PubMedGoogle Scholar
• Mitchell MS. Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 2003; 52: 686–92
   PubMed Web of Science ®Google Scholar
• Nicolini A, Carpi A, Ferrari P, Sagripanti A, Anselmi L. A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. Biomed Pharmacother 1998; 52: 311–6
   PubMedGoogle Scholar
• Gebbia V, Testa A, Majello E, Cannata G, Tirrito ML, Mastrandrea G, et al. Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma. Anticancer Drugs 1996; 7: 386–91
   PubMedGoogle Scholar
• Prat A, Casado E, Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007; 13: 5857–66
   PubMed Web of Science ®Google Scholar
• Moosmann N, Heinemann V. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther 2008; 8: 319–29
   PubMed Web of Science ®Google Scholar
• Mahtani RL, Macdonald JS. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Oncologist 2008; 13: 39–50
   PubMedGoogle Scholar
• Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005; 5: 171–93
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232–9
   PubMed Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039–49
   PubMed Web of Science ®Google Scholar
• June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466–76
   PubMed Web of Science ®Google Scholar
• Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML. Adoptive T-cell therapy for the treatment of solid tumours. Expert Opin Biol Ther 2002; 2: 55–66
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704–15
   PubMed Web of Science ®Google Scholar
• Riddell SR. Engineering antitumor immunity by T-cell adoptive immunotherapy. Hematology Am Soc Hematol Educ Program 2007; 2007: 250–6
   Google Scholar
• Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 2002; 8: 1767–71
   PubMed Web of Science ®Google Scholar
• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54: 187–207
   PubMed Web of Science ®Google Scholar
• Burgdorf SK, Claesson MH, Rosenberg J. Dendritic cell-based cancer vaccine. Ugeskr Laeger 2006; 168: 1420–3
   PubMedGoogle Scholar
• Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008; 68: 889–92
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1: 362–8
   PubMed Web of Science ®Google Scholar
• Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 2007; 30: 762–72
   PubMed Web of Science ®Google Scholar
• Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of the digestive tract. World J Gastroenterol 2003; 9: 495–8
   PubMed Web of Science ®Google Scholar
• Burgdorf SK, Fischer A, Claesson MH, Kirkin AF, Dzhandzhugazyan KN, Rosenberg J. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. J Exp Clin Cancer Res 2006; 25: 201–6
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345–50
   PubMed Web of Science ®Google Scholar
• Cubas R, Li M, Chen C, Yao Q. Colorectal cancer: new advances in immunotherapy. Cancer Biol Ther 2007; 6: 11–7
   PubMed Web of Science ®Google Scholar
• Copier J, Ward S, Dalgleish A. Cell-based cancer vaccines: regulatory and commercial development. Vaccine 2007; 25(Suppl 2)B35–46
   Google Scholar
• Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007; 13: 4487–94
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38: 1000–15
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Christensen IJ, Brunner NA. Serological markers of colorectal cancer. Ugeskr Laeger 2005; 167: 4163–7
   PubMedGoogle Scholar
• Lurje G, Zhang W, Lenz HJ. Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer 2007; 6: 683–90
   PubMedGoogle Scholar
• Duffy MJ, van DA, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348–60
   PubMed Web of Science ®Google Scholar
• Ahmed FE. Molecular markers that predict response to colon cancer therapy. Expert Rev Mol Diagn 2005; 5: 353–75
   PubMed Web of Science ®Google Scholar
• Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P, et al. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res 2007; 13: 4016–25
   PubMed Web of Science ®Google Scholar
• Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131–8
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008; 134: 1296–310
   PubMed Web of Science ®Google Scholar
• Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. Microsatellite instability in colorectal cancer. Br J Surg 2006; 93: 395–406
   PubMed Web of Science ®Google Scholar
• Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113–30
   PubMed Web of Science ®Google Scholar
• Speetjens FM, Lauwen MM, Franken KL, Janssen-van Rhijn CM, van DS, Bres SA, et al. Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int J Cancer 2008; 123: 838–45
   PubMedGoogle Scholar
• Baker K, Foulkes WD, Jass JR. MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8(+) T cells. Cancer Immunol Immunother 2008. Epub ahead of print.
   PubMedGoogle Scholar
• Atreya I, Neurath MF. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 2008; 8: 561–72
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, et al. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res 2007; 67: 10012–8
   PubMedGoogle Scholar